"The diagnostic odyssey of the infrequent: Creutzfeldt-Jakob disease, apropos of a case."
DOI:
https://doi.org/10.5281/zenodo.17185922Keywords:
Creutzfeldt-Jakob disease, Rapidly progressive dementia, Spongiform encephalopathy, Prion.Abstract
Creutzfeldt–Jakob disease (CJD) is a rare, spongiform encephalopathy characterized by rapidly progressive neurological deterioration and fatal outcomes. This report presents the case of a 39-year-old male who presented to the emergency department with behavioral disturbances, insomnia, and subacute-onset neuropsychiatric symptoms. He was admitted to a tertiary care center for evaluation and treatment, where his condition rapidly progressed to severe dementia, ataxia, apraxia, dysphagia and respiratory compromise, which eventually led to his death. Brain imaging revealed hyperintensities in the basal ganglia and cerebral cortex, these findings consistent with CJD. Cerebrospinal fluid analysis detected the PRNP M129M genotype and the E200K mutation, highly suggestive of a genetic form of CJD. This case highlights the importance of early recognition of CJD and the need to include it in the differential diagnosis of rapidly progressive dementia, even in younger patients.
Downloads
References
[1] Hermann P, Appleby B, Brandel JP, et al. Biomarkers and diagnostic guidelines for sporadic Creutzfeldt–Jakob disease. Lancet Neurol. 2021;20(3):235–246. Available from: https://pubmed.ncbi.nlm.nih.gov/33609480/ PubMed
[2] Pokorna A, Rychlik T, Martinec P, et al. Spectrum and pattern of movement disorders in patients with prion diseases. J Mov Disord. 2023;16(1):8–20. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10162196/ PMC
[3] Pal S, Brandel JP, Watson N. The importance of ongoing international surveillance for Creutzfeldt–Jakob disease. Nat Rev Neurol. 2021;17(6):277–290. Available from: https://www.nature.com/articles/s41582-021-00488-7 Nature
[4] Centers for Disease Control and Prevention. Clinical Overview of Creutzfeldt–Jakob Disease (CJD) [Internet]. Updated 2024 [cited 2025 May 13]. Available from: https://www.cdc.gov/creutzfeldt-jakob/hcp/clinical-overview/index.html CDC
[5] Conchillo-Solé O, Ramírez-Zamora A, Green AJ, et al. The use of real‑time quaking-induced conversion for the diagnosis of human prion diseases. Front Aging Neurosci. 2022;14:874734. Available from: https://www.frontiersin.org/articles/10.3389/fnagi.2022.874734/full Frontiers
[6] Creutzfeldt-Jakob Disease Fact Sheet. CJD Foundation [Internet]. 2021 [cited 2025 May 13]. Available from: https://cjdfoundation.org/shared-files/5696/?CJD-FACT-SHEET-2021.pdf CJD Foundation
[7] Zamora L, Ruiz A, Martínez-Vivaldi I, et al. Systematic review of pharmacological management in Creutzfeldt–Jakob disease. J Neurol Sci. 2022;442:120360. Available from: https://www.ncbi.nlm.nih.gov/articles/PMC9703894/ PMC
[8] McGuire LI, Peden AH, Orrú CD, et al. Prion protein monoclonal antibody (PRN100) therapy for Creutzfeldt–Jakob disease: a phase I safety trial. Lancet Neurol. 2022;21(8):720–729. Available from: https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(22)00082-5/fulltext The Lancet
[9] Centers for Disease Control and Prevention. About Prion Diseases [Internet]. Updated 2024 [cited 2025 May 13]. Available from: https://www.cdc.gov/prions/about/index.html CDC
[10] Pathological spectrum of sporadic Creutzfeldt–Jakob disease. Pathology. 2024;56(2):190–202. Available from: https://www.pathologyjournal.rcpa.edu.au/article/S0031-3025(24)00289-7/fulltext
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Mackarena González Delgadillo, Maximiliano Fuenzalida Boye, Lukas León Cortés, María Florencia Polanco Vargas, Alex Cáceres Brito (Autor/a)

This work is licensed under a Creative Commons Attribution 4.0 International License.